Solventum (NYSE:SOLV) Earns Neutral Rating from Analysts at Mizuho

Mizuho started coverage on shares of Solventum (NYSE:SOLV) in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a neutral rating and a $70.00 price objective on the stock.

Several other equities analysts also recently weighed in on SOLV. The Goldman Sachs Group raised their price target on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Stifel Nicolaus initiated coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. Morgan Stanley upped their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler raised their price target on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Finally, Wolfe Research started coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Solventum has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Stock Performance

Solventum stock opened at $69.96 on Wednesday. Solventum has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock’s 50 day moving average is $70.65 and its 200 day moving average is $62.82.

Hedge Funds Weigh In On Solventum

Institutional investors and hedge funds have recently modified their holdings of the company. Deseret Mutual Benefit Administrators bought a new position in Solventum in the second quarter valued at about $25,000. Hollencrest Capital Management bought a new position in shares of Solventum in the 2nd quarter worth approximately $25,000. Richard W. Paul & Associates LLC purchased a new position in shares of Solventum during the 2nd quarter worth $26,000. Family Firm Inc. bought a new stake in shares of Solventum during the 2nd quarter valued at $26,000. Finally, Copeland Capital Management LLC purchased a new stake in shares of Solventum in the 3rd quarter worth $26,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.